Homepage > Company > Media > Pharma News > 2019 > Sanofi agrees to sell Seprafilm to Baxter for $350 million

Sanofi agrees to sell Seprafilm to Baxter for $350 million

PARIS (Reuters) - Medical supply company Baxter International Inc (BAX.N) said on Monday it had agreed to buy Sanofi (SASY.PA)’s Seprafilm unit, which makes specialist surgical products, for $350 million in cash.

The deal should close by the end of the first quarter of2020, Baxter added in a statement confirming the purchase, which was reported earlier by Reuters.

France’s Sanofi is conducting a broad strategy review under new chief executive Paul Hudson, who will give some initial pointers on which businesses he wants to focus on at an investor day on Dec. 10.

“As part of our ongoing strategic transformation, we are refocusing our established products portfolio to allow for focus on key growth platforms,” a spokesman with Sanofi said.

The company took on Seprafilm, which is used to help manage bleeding in abdominal and pelvis operations, in 2011 as part of its purchase of Genzyme.

DECEMBER 2, 2019

https://www.reuters.com/

Read also

AskBio’s AB-1002 gene therapy receives FDA Fast-Track status

The US Food and Drug Administration (FDA) has granted fast-track designation to Bayer subsidiary Asklepios BioPharmaceutical’s (AskBio) investigational gene therapy AB-1002, aimed at...

“Lack of harmonisation in Europe” hindering gene therapy growth

The future of cell and gene therapy access in Europe could be more precarious than across the pond.

Moderna stock on track for the eighth consecutive day of losses

Moderna shares are trading in the red on Friday, on track for the eighth consecutive day of losses. Stock down 1.28% at $100.70. MRNA has lost about 29.6% in the last 12 months and YTD, the st...

Alvotech moves to bring its Humira biosimilar to US market

Hot on the heels of a US Food and Drug Administration (FDA) approval for Alvotech and Teva Pharmaceuticals’ Simlandi (adalimumab-ryvk), Alvotech has announced a long-term agreement w...